1. A pharmaceutical agent, where the agent contains one or more peptides capable of inducing a cytotoxic T-lymphocyte (CTL), where the peptide contains an amino acid sequence that is selected from the group consisting of:! (a) SEQ ID NO: 1, and 2； and! (b) SEQ ID NO: 1, and 2, where 1, 2 or more amino acids are substituted, inserted, deleted and / or added,! or one or more polynucleotides encoding such a peptide, in combination with a pharmacologically acceptable carrier, and is formulated for a purpose that is selected from the group consisting of:! (i) treating cancer in a patient in whom the HLA-A antigen is HLA-A0206,! (ii) cancer prevention in a patient in whom the HLA-A antigen is HLA-A0206,! (iii) preventing postoperative cancer recurrence in a patient in whom the HLA-A antigen is HLA-A0206, and! (iv) combinations thereof. ! 2. The pharmaceutical agent of claim 1, wherein said cancer is selected from the group consisting of bladder cancer, cervical cancer, cholangiocellular carcinoma, esophageal cancer, gastric cancer, non-small cell lung cancer (NSCLC), osteosarcoma, pancreatic cancer, renal carcinoma and soft tissue tumors. ! 3. The pharmaceutical agent according to claim 1, which is made up in the form of a vaccine. ! 4. A method for inducing an antigen-presenting cell having a high ability to induce CTLs, where the method includes a step that is selected from the group consisting of the following:! (a) contacting the antigen presenting cell with a peptide that contains an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 2, or such a peptide in which at least one amino acid is added, inserted, deleted, and / or substituted by another amino acid； and! (b) introduction1. Фармацевтическое средство, где средство содержит один или несколько пептидов, способных индуцировать цитотоксический T-лимфоцит (ЦТЛ), где пептид содержит аминокислотную последовательность, которая выбрана из группы, состоящей из: ! (a) SEQ ID NO:1, и 2； и ! (b) S
